Updated NCCN guidelines include cosibelimab as a Category 2A recommended treatment option for patients with locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or radiation, supported by clinical...
Updated NCCN guidelines include cosibelimab as a Category 2A recommended treatment option for patients with locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or radiation, supported by clinical...
A retrospective cohort study found that limited PD-1 exposure frequently produced durable disease control in patients with locally advanced or resectable cutaneous squamous cell carcinoma, with uncertain incremental benefit from treatment...
A retrospective cohort study found that limited PD-1 exposure frequently produced durable disease control in patients with locally advanced or resectable cutaneous squamous cell carcinoma, with uncertain incremental benefit from treatment...
A multidisciplinary Delphi consensus established staging and surveillance imaging recommendations for localized cutaneous squamous cell carcinoma, supporting imaging for tumors with at least a 15% risk of metastasis and identifying specific...
A multidisciplinary Delphi consensus established staging and surveillance imaging recommendations for localized cutaneous squamous cell carcinoma, supporting imaging for tumors with at least a 15% risk of metastasis and identifying specific...
Results from the phase 3 C-POST trial demonstrated that adjuvant cemiplimab significantly improved disease-free survival compared with placebo among patients with high-risk cSCC.
Results from the phase 3 C-POST trial demonstrated that adjuvant cemiplimab significantly improved disease-free survival compared with placebo among patients with high-risk cSCC.
Results from a secondary analysis of the phase 3 TROG 05.01 trial identified a subgroup of patients with high-risk cutaneous squamous cell carcinoma of the head and neck who experienced significantly worse survival following postoperative...
Results from a secondary analysis of the phase 3 TROG 05.01 trial identified a subgroup of patients with high-risk cutaneous squamous cell carcinoma of the head and neck who experienced significantly worse survival following postoperative...
Results from a nationwide, population-based study demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ increased steadily over nearly two decades, highlighting the growing burden...
Results from a nationwide, population-based study demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ increased steadily over nearly two decades, highlighting the growing burden...
Medicare coverage has been extended to serial Signatera molecular residual disease testing for surveillance of patients with early-stage hepatocellular carcinoma who have no evidence of disease following surgery, supported by real-world...
Medicare coverage has been extended to serial Signatera molecular residual disease testing for surveillance of patients with early-stage hepatocellular carcinoma who have no evidence of disease following surgery, supported by real-world...
The phase 3 IMpactMF trial of imetelstat in patients with JAK inhibitor-relapsed or refractory myelofibrosis has been discontinued after an independent Data Monitoring Committee determined that the study was unlikely to meet its primary...
The phase 3 IMpactMF trial of imetelstat in patients with JAK inhibitor-relapsed or refractory myelofibrosis has been discontinued after an independent Data Monitoring Committee determined that the study was unlikely to meet its primary...
Updated NCCN guidelines include cosibelimab as a Category 2A recommended treatment option for patients with locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or radiation, supported by clinical...
Updated NCCN guidelines include cosibelimab as a Category 2A recommended treatment option for patients with locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or radiation, supported by clinical...
Results from the phase 3 LiGeR-HN1 trial demonstrated that petosemtamab plus pembrolizumab significantly improved overall survival and objective response compared with pembrolizumab alone in patients with PD-L1-positive recurrent or...
Results from the phase 3 LiGeR-HN1 trial demonstrated that petosemtamab plus pembrolizumab significantly improved overall survival and objective response compared with pembrolizumab alone in patients with PD-L1-positive recurrent or...
Results from the phase 2 BELLA trial demonstrated encouraging progression-free survival and response with relacorilant plus nab-paclitaxel and bevacizumab in patients with platinum-resistant ovarian cancer, with more pronounced activity among...
Results from the phase 2 BELLA trial demonstrated encouraging progression-free survival and response with relacorilant plus nab-paclitaxel and bevacizumab in patients with platinum-resistant ovarian cancer, with more pronounced activity among...
Updated ASTRO clinical practice guidelines recommend moderate hypofractionated radiotherapy over conventional fractionation across all localized prostate cancer risk groups and expand the role of ultrahypofractionation, including stereotactic...
Updated ASTRO clinical practice guidelines recommend moderate hypofractionated radiotherapy over conventional fractionation across all localized prostate cancer risk groups and expand the role of ultrahypofractionation, including stereotactic...
Results from the phase 4 Jazz EMERGE 402 study demonstrated clinically meaningful antitumor activity with lurbinectedin in previously treated small cell lung cancer, with lower response rates among patients with baseline central nervous...
Results from the phase 4 Jazz EMERGE 402 study demonstrated clinically meaningful antitumor activity with lurbinectedin in previously treated small cell lung cancer, with lower response rates among patients with baseline central nervous...
Results from a large NETSARC+ registry analysis demonstrated a substantial decline in surgical management of desmoid tumors over time and identified tumor size and anatomical location as prognostic factors for progression-free survival,...
Results from a large NETSARC+ registry analysis demonstrated a substantial decline in surgical management of desmoid tumors over time and identified tumor size and anatomical location as prognostic factors for progression-free survival,...
Results from a multicenter, retrospective trial demonstrated that granulocyte colony-stimulating factor prophylaxis was associated with significantly reduced febrile neutropenia rates and fewer related acute-care visits in patients with small...
Results from a multicenter, retrospective trial demonstrated that granulocyte colony-stimulating factor prophylaxis was associated with significantly reduced febrile neutropenia rates and fewer related acute-care visits in patients with small...
Results from the phase 3 TAISHAN-302 trial demonstrated that tambotatug pelitecan significantly improved overall survival, progression-free survival, and objective response compared with topotecan in patients with relapsed small cell lung...
Results from the phase 3 TAISHAN-302 trial demonstrated that tambotatug pelitecan significantly improved overall survival, progression-free survival, and objective response compared with topotecan in patients with relapsed small cell lung...
